Latest News - Acucela

Friday, January 27, 2017 | Clinical Trials, Acucela

Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease

Acucela announced that on January 25, 2017, the first patient was enrolled in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride, in subjects with macular atrophy seco…

Read the full story

Friday, January 06, 2017 | FDA Approval/Clearance, Acucela, AMD

Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease

Acucela announced that the FDA granted orphan drug designation to Acucela’s leading drug candidate emixustat hydrochloride for the treatment of Stargardt disease. The orphan drug designation doe…

Read the full story

Wednesday, December 14, 2016 | Acquisitions/Mergers, Acucela, AMD

Acucela Secures Option to Exclusively Acquire Novel Retinal Technology

Acucela announced an R&D agreement and exclusive option to acquire the global rights to EyeMedics' proprietary biomimetic technology, including an initial candidate molecule for ophthalmic use…

Read the full story

Tuesday, June 14, 2016 | Earnings & Financials, Acucela

Acucela Announces Termination of Emixustat Agreement and OPA-6566 Agreement with Otsuka Pharmaceutical, and Postponement of Annual Shareholder Meeting

Acucela announced that the company received a written termination notice from Otsuka Pharmaceutical for the codevelopment and commercialization agreement between the company and Otsuka Pharmaceutical …

Read the full story

Thursday, May 26, 2016 | Clinical Trials, Acucela

Phase 2b/3 Clinical Trial of Acucela's Emixustat Does Not Meet Primary Endpoint

Acucela announced top-line results from the phase 2b/3 clinical trial (SEATTLE study) of the investigational visual cycle modulator emixustat hydrochloride (emixustat), according to a company news rel…

Read the full story

Monday, May 09, 2016 | Clinical Trials, Acucela

Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy

Acucela announced that the company initiated a phase 2 clinical trial with the enrollment of the first patient to assess the benefits of emixustat hydrochloride (emixustat) for the treatment of prolif…

Read the full story

Tuesday, April 05, 2016 | Retina, Acucela

Acucela Licenses Gene Therapy from The University of Manchester for Retinal Degenerative Disease

Acucela and The University of Manchester, UK, announced an exclusive license agreement whereby Acucela will develop and commercialize University of Manchester’s human rhodopsin based optogenetic…

Read the full story

Thursday, March 17, 2016 | Cataract Surgery, Partnerships, Acucela

Acucela Secures Option to Exclusively License Non-Surgical Cataract Treatment

Acucela and YouHealth Eyetech announced an agreement involving an exclusive option from YouHealth on lanosterol technology licensed from the Regents of the University of California, San Diego for the …

Read the full story

Thursday, November 05, 2015 | Medical Studies, Acucela

Acucela Says It Validates Sampling Method That Could Pave Way for More Efficient Clinical Tests

Acucela has validated an analytical method that could lead to significant cost savings in the collection of blood samples as part of the company’s clinical trials of emixustat hydrochloride (emi…

Read the full story

Wednesday, August 05, 2015 | Management/Leadership, Acucela

Acucela Hires Dr. Lukas Scheibler as Executive Vice President of Translational Medicine

Acucela announced that it has hired Lukas Scheibler, PhD, as executive vice president of Translational Medicine. Dr. Scheibler joins Acucela after a 13-year career in research and development, busines…

Read the full story

Friday, June 05, 2015 | Clinical Trials, Acucela

Acucela Announces Publication of Phase 2a Clinical Trial Results for Emixustat Hydrochloride

Acucela announced the publication of results from a phase 2a clinical trial of emixustat hydrochloride (emixustat) in patients with geographic atrophy associated with dry age-related macular degenerat…

Read the full story

Tuesday, May 19, 2015 | Management/Leadership, Acucela

Acucela Nominates Shintaro Asako to Its Board of Directors

Acucela has announced that it has nominated Shintaro Asako to stand for election to the company’s board of directors at the 2015 annual meeting of shareholders on June 25, 2015 at Acucela’…

Read the full story

Thursday, May 14, 2015 | Clinical Trials, Acucela

Acucela Announces Publication of Preclinical Data for Emixustat Hydrochloride

Acucela announced the publication of preclinical data related to the company’s investigational drug candidate, emixustat hydrochloride (emixustat), in the scientific journal PLOS ONE, according …

Read the full story

Monday, May 04, 2015 | Management/Leadership, Acucela

Acucela Shareholders Elect New Board Members

Acucela announced that shareholders have elected four new members to the company’s board of directors at a special meeting of the company’s shareholders, according to a company news releas…

Read the full story

Monday, April 27, 2015 | Earnings & Financials, Acucela

Acucela Provides Company Updates

Acucela announced that it has made progress on the three strategic imperatives previously announced in its 2014 Annual Report to Shareholders to increase the value of the company and enhance sharehold…

Read the full story